GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLAW) » Definitions » Total Stockholders Equity

Estrella Immunopharma (Estrella Immunopharma) Total Stockholders Equity : $8.50 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Total Stockholders Equity?

Estrella Immunopharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $8.50 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Estrella Immunopharma's Book Value per Share for the quarter that ended in Mar. 2024 was $N/A. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Estrella Immunopharma's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.00.

Estrella Immunopharma Total Stockholders Equity Historical Data

The historical data trend for Estrella Immunopharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Total Stockholders Equity Chart

Estrella Immunopharma Annual Data
Trend Jun21
Total Stockholders Equity
-

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.48 - 10.07 9.05 8.50

Estrella Immunopharma  (NAS:ESLAW) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Estrella Immunopharma's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(8.495-0)/0
=N/A

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Estrella Immunopharma's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 8.495
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Estrella Immunopharma Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Estrella Immunopharma (Estrella Immunopharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLAW) » Definitions » Total Stockholders Equity
Comparable Companies
EYEN FGEN ADCT VANI IPA AFMD KNTE KZR SABS ELTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
ESLA:USA
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Website
https://www.estrellabio.com
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines